Oragenics Inc. (OGEN) shares declined 5.57% in after-hours on Tuesday, July 27, 2021, and closed the Tuesday trading at $0.79 per share. In the regular trading session of Tuesday, OGEN’s stock gained 34.14%. OGEN shares have fallen 28.92% over the last 12 months, and they have moved up 35.88% in the past week. Over the past three months, the stock has gained 3.56%, while over the past six months, it has reduced 20.11%. The company has a current market of $99.95 million and its outstanding shares stood at 115.64 million.
Let’s see what are the latest news about OGEN?
OGEN Licensing Agreement with the National Research Council of Canada
On July 27, 2021, Oragenics, Inc (OGEN) entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
The NRC technologies, in combination with the U.S. National Institutes of Health (NIH) elements found in the Company’s Terra CoV-2 vaccine, provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern in a very short span of time.
OGEN adjourned the annual meeting of shareholders
Oragenics, Inc. (OGEN) annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.
OGEN Letter to Shareholders
On May 18, 2021, the executive Chairman of Oragenics Inc, Frederick W. Telling, Ph.D. issued a letter to the company’s shareholders.
He said that the company is working quickly to develop the Terra CoV-2 vaccine candidate to address SARS-CoV-2 and its variants, as well as a new class of antibiotics to address the daunting problem of antibiotic resistance.
OCGN Overhaul in Management and Board of Directors
On May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President, and director of Oragenics, Inc (OGEN).
Mr. Sullivan, the OGEN current Chief Financial Officer, will serve as the Company’s interim principal executive officer to address the vacancy created by Dr. Joslyn’s resignation.
Also, Dr. Frederick Telling transitioned from Chairman of the Board to the newly established position of Executive Chairman, effective immediately, during the interim period before a new CEO is hired.
OGEN CoV-2 S-2P demonstrated protective immunity in mice
In February 2021, Oragenics, Inc released the data from the National Institutes of Health (NIH) that confirmed the stabilized prefusion spike protein CoV-2 S-2P induced protective immunity in mice challenged with mouse-adapted SARS-CoV-2 virus.
OGEN Material transfer agreement with Biodextris
On March 9, 2021, Oragenics (OGEN) entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19.
Conclusion
OGEN stock surged on Tuesday after it announced a recent agreement with the National Research Council of Canada. There was no reason behind its loss in the after-hours and we expect it to return towards positivity on Wednesday.
